Buy Zydus Lifesciences; target of Rs 1100: Sharekhan

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 20, 2024.
21-03-2024

Zydus Lifesciences rises 2% on launch of cancer drug Olaparib

The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.
14-03-2024
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Zydus Family Trust & PACs
12-03-2024

Buy Zydus Lifesciences; target of Rs 1006: KR Choksey

KR Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1006 in its research report dated March 06, 2024.
07-03-2024

Zydus Lifesciences' Rs 600 Crore Buyback Offer To Open On Feb 29

Zydus Lifesciences' Rs 600 crore buyback offer for 59.7 lakh shares at Rs 1,005 each opens on Feb 29 and closes on March 6, 2024.
27-02-2024
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Reply To Clarification Sought On Increase In Volume Of Shares

Reply to clarification sought on increase in volume of shares
26-02-2024
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Zydus Family Trust & PACs
26-02-2024
Next Page
Close

Let's Open Free Demat Account